Drugs / Reinovax PCV24 formulation 1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06678607 | Nov 2023 → Jul 2024 | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06678620 | Apr 2024 → Apr 2025 overdue | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reinovax PCV24 formulation 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06678607 ↗ |
| Known as | 24-valent pneumococcal conjugate vaccine | “Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.” NCT06678607 ↗ |
| Modality | Vaccine | “24-valent pneumococcal conjugate vaccine (PCV24)” NCT06678607 ↗ |
| Route | Intramuscular | “The route of administration is intramuscular injection at the deltoid muscle of the upper arm.” NCT06678607 ↗ |